Abivax Raises $920 Million to Fund U.S. Launch of Bowel Disease Drug
French biotech Abivax has raised $920 million, allowing it to prepare for a solo U.S. launch of its bowel disease drug obefazimod without relying on Big Pharma backing. The funding will finance operations through 2029 and support further clinical development.
Tickers: $ABVX
Topics: drug_launch funding takeover_speculation